RonaldCRubensteinMDPhD

Cystic Fibrosis Pulmonology

Professor and Chief, Allergy and Pulmonary Medicine, Robert C. Strunk Endowed Chair for Lung and Respiratory Research, Department of Pediatrics, Washington University in St. Louis School of Medicine and St. Louis Children's Hospital St. Louis, MO

Join to view full profile

Dr. Rubenstein is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. Rubenstein's full profile

Already have an account?

Office
1 Childrens Pl
# Div
Saint Louis, MO 63110
Phone+1 314-454-2694

Fax+1 314-454-2515

Education & Training

Johns Hopkins UniversityFellowship, Pediatric Pulmonology, 1994 - 1997
UPMC Medical EducationResidency, Pediatrics, 1991 - 1994
University of Texas Southwestern Medical SchoolClass of 1991

Certifications & Licensure

IL State Medical License 2022 - 2026
MO State Medical License 2020 - 2025
PA State Medical License 1993 - 2024
MD State Medical License 1994 - 2005
American Board of Pediatrics Pediatric Pulmonology

Clinical Trials

Phenylbutyrate/Genistein Duotherapy in Delta F508-Homozygous(for Cystic Fibrosis) Start of enrollment: 2001 Sep 01
Completed
Phase 1, Phase 2
Nasal Potential Difference (NPD) for the Diagnosis of Cystic Fibrosis Start of enrollment: 2003 Sep 01
Completed
Not Applicable
Phenylbutyrate/Genistein Duotherapy in Delta F508-Heterozygotes (for Cystic Fibrosis) Start of enrollment: 2003 Feb 01
Terminated
Phase 1, Phase 2
Baby Observational and Nutritional Study Start of enrollment: 2011 Dec 01
Completed
G551D Observational Study- Expanded to Additional Genotypes and Extended for Long Therm Follow up (GOAL-e2) Start of enrollment: 2014 Jan 01
Completed
Ivacaftor (Kalydeco) and Insulin in Cystic Fibrosis (CF) Start of enrollment: 2014 Jan 06
Completed
Join now to see all

Publications & Presentations

PubMed

176 citations
Ivacaftor treatment of cystic fibrosis in children aged 12 to <24 months and with a CFTR gating mutation (ARRIVAL): a phase 3 single-arm study
Margaret Rosenfeld, Claire E. Wainwright, Mark Higgins, Linda T Wang, Charlotte M. McKee
The Lancet. Respiratory Medicine. 2018-07-01
223 citations
Sodium 4-phenylbutyrate downregulates Hsc70: implications for intracellular trafficking of ΔF508-CFTR
Ronald C. Rubenstein, Pamela L. Zeitlin
American Journal of Physiology. Cell Physiology. 2000-02-01
25 citations
Cystic Fibrosis Foundation otolaryngology care multidisciplinary consensus recommendations.
Adam J Kimple, Brent A Senior, Edward T Naureckas, David A Gudis, Ted Meyer
International Forum of Allergy & Rhinology. 2022-09-01

Press Mentions

Board Grants Faculty Appointments, Promotions, TenureJune 7th, 2021
The Newly Retired FacultyMay 25th, 2021
Power of the PupJune 22nd, 2020

Grant Support

Deltaf508-Cftr Trafficking Regulated By 4-PhenylbutyrateNational Institute Of Diabetes And Digestive And Kidney Diseases2004–2012
Regulatory Interactions Of CFTR And ENACNational Institute Of Diabetes And Digestive And Kidney Diseases2009–2010
Phenylbutyrate/Genistein Duotherapy In Deltaf508 HeterozygotesNational Center For Research Resources2004–2005
A Pilot Trial Of Phenylbutyrate/Genistein Duotherapy (For Cystic Fibrosis)National Center For Research Resources2004–2005
Deltaf508-Cftr Trafficking Regulated By 4-PhenylbutyrateNational Institute Of Diabetes And Digestive And Kidney Diseases2000–2003
Cystic Fibrosis Lung Disease Using A 3rd Generation AdenovirusNational Center For Research Resources2000–2002
CAMP Stimulated Sweat Rate In Cystic FibrosisNational Center For Research Resources1998–2002